All Relations between Neurodegenerative Diseases and substantia nigra compacta

Reference Sentence Publish Date Extraction Date Species
Christian Ardianto, Robert Shen, Jimmy F A Barus, Poppy Kristina Sasmita, Yuda Turana, Lilis Lilis, Veronika Maria Sidhart. Secretome as neuropathology-targeted intervention of Parkinson's disease. Regenerative therapy vol 21 issue 2022 36092507 parkinson's disease (pd) is the second most common progressive neurodegenerative disease, characterized by apoptosis of dopaminergic neurons in substansia nigra pars compacta (snpc) caused by \xe2\x8d\xba-synuclein aggregation. 2022-09-12 2022-09-14 Not clear
Nicola Montemurro, Nelida Aliaga, Pablo Graff, Amanda Escribano, Jafeth Lizan. New Targets and New Technologies in the Treatment of Parkinson's Disease: A Narrative Review. International journal of environmental research and public health vol 19 issue 14 2022 35886651 parkinson's disease (pd) is a progressive neurodegenerative disease, whose main neuropathological finding is pars compacta degeneration due to the accumulation of lewy bodies and lewy neurites, and subsequent dopamine depletion. 2022-07-27 2022-08-08 Not clear
Theodora Mourtzi, Ilias Kazani. Endogenous Neural regeneration research vol 17 issue 12 2022 35662194 endogenous parkinson's disease is the second most common neurodegenerative disease and has currently no effective treatment, one that would be able to stop or reverse the loss of dopaminergic neurons in the substantia nigra pars compacta. 2022-06-06 2022-06-13 Not clear
Hung-Te Hsu, Ya-Lan Yang, Wan-Hsuan Chang, Wei-Yu Fang, Shu-Hung Huang, Shah-Hwa Chou, Yi-Ching L. Hyperbaric Oxygen Therapy Improves Parkinson's Disease by Promoting Mitochondrial Biogenesis via the SIRT-1/PGC-1\\xce\\xb1 Pathway. Biomolecules vol 12 issue 5 2022 35625589 pd is a neurodegenerative disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (snpc). 2022-05-28 2022-06-13 Not clear
Deepika Np, Md Habibur Rahman, Sandhya Chipurupalli, Shilpa Tn, Basavan Duraiswam. Emerging Role of Marine Natural Products for the Treatment of Parkinson's Disease. CNS & neurological disorders drug targets vol issue 2022 35546747 parkinson's disease (pd), known as parkinsonism, is a neurodegenerative disease that mainly affects the elderly and is characterized by an extensive and progressive loss of dopaminergic neurons in the substantia nigra pars compacta (snpc). 2022-05-13 2022-06-13 Not clear
Jianjun Xu, Etsuko Minobe, Masaki Kameyam. Ca Frontiers in cellular neuroscience vol 16 issue 2022 35496903 ca parkinson's disease (pd), a common neurodegenerative disease characterized by motor dysfunction, results from the death of dopaminergic neurons in the substantia nigra pars compacta (snc). 2022-05-02 2022-05-03 Not clear
Katarzyna Kaczy\\xc5\\x84ska, Magdalena Ewa Or\\xc5\\x82owska, Kryspin Andrzejewsk. Respiratory Abnormalities in Parkinson's Disease: What Do We Know from Studies in Humans and Animal Models? International journal of molecular sciences vol 23 issue 7 2022 35408858 parkinson's disease (pd) is the second most common progressive neurodegenerative disease characterized by movement disorders due to the progressive loss of dopaminergic neurons in the ventrolateral region of the substantia nigra pars compacta (snpc). 2022-04-12 2022-04-14 Not clear
Tao Dang, Wen-Jing Cao, Rong Zhao, Ming Lu, Gang Hu, Chen Qia. ATP13A2 protects dopaminergic neurons in Parkinson's disease: from biology to pathology. Journal of biomedical research vol issue 2022 35387901 as we all know, pd is a neurodegenerative disease characterized by the loss of da neurons in the substantia nigra pars compacta. 2022-04-07 2022-04-14 Not clear
Ruixian Xing, Xuewen Liu, Buxian Tian, Yan Cheng, Longguang L. Neuroprotective effect of Na Drug development research vol 82 issue 7 2021 33538000 neuroprotective effect of na parkinson's disease (pd) is a disabling neurodegenerative disease mainly caused by degeneration of mesencephalic dopaminergic neurons in the substantia nigra pars compacta (snpc). 2022-02-03 2022-01-13 Not clear
Ayumi E Pottenger, Mitchell J Bartlett, Scott J Sherman, Torsten Falk, Helena W Morriso. Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment. Neuroscience letters vol 765 issue 2022 34536508 parkinson's disease (pd) is a neurodegenerative disease caused by the death of dopaminergic neurons in the substantia nigra pars compacta (snpc), characterized by motor dysfunction. 2022-01-10 2022-01-13 Not clear
Lan-Hsin Nancy Lee, Chen-Syuan Huang, Hsiang-Hao Chuang, Hsing-Jung Lai, Cheng-Kai Yang, Ya-Chin Yang, Chung-Chin Ku. An electrophysiological perspective on Parkinson's disease: symptomatic pathogenesis and therapeutic approaches. Journal of biomedical science vol 28 issue 1 2021 34886870 parkinson's disease (pd), or paralysis agitans, is a common neurodegenerative disease characterized by dopaminergic deprivation in the basal ganglia because of neuronal loss in the substantia nigra pars compacta. 2021-12-10 2022-01-13 Not clear
Hongli Li, Yaru Feng, Ziyu Chen, Xi Jiang, Zhenyu Zhou, Jinfeng Yuan, Fei Li, Yu Zhang, Xingxu Huang, Shengjie Fan, Xiaojun Wu, Cheng Huan. Pepper component 7-ethoxy-4-methylcoumarin, a novel dopamine D2 receptor agonist, ameliorates experimental Parkinson's disease in mice and Caenorhabditis elegans. Pharmacological research vol 163 issue 2021 33007422 parkinson's disease (pd) is a progressive neurodegenerative disease resulting from the degeneration of dopaminergic (daergic) neurons in the substantia nigra pars compacta (snpc) and subsequent deficit of dopamine in the striatum. 2021-11-18 2022-01-13 Not clear
Ruixian Xing, Xuewen Liu, Buxian Tian, Yan Cheng, Longguang L. Neuroprotective effect of Na Drug development research vol 82 issue 7 2021 33538000 neuroprotective effect of na parkinson's disease (pd) is a disabling neurodegenerative disease mainly caused by degeneration of mesencephalic dopaminergic neurons in the substantia nigra pars compacta (snpc). 2021-11-15 2022-01-13 Not clear
Henrik Renner, Hans R Sch\\xc3\\xb6ler, Jan M Brude. Combining Automated Organoid Workflows With Artificial Intelligence-Based Analyses: Opportunities to Build a New Generation of Interdisciplinary High-Throughput Screens for Parkinson's Disease and Beyond. Movement disorders : official journal of the Movement Disorder Society vol issue 2021 34498298 parkinson's disease (pd) is the second most common neurodegenerative disease and primarily characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta of the midbrain. 2021-09-20 2022-01-13 Not clear
Luca Magistrelli, Elena Contaldi, Cristoforo Com. The Impact of Life (Basel, Switzerland) vol 11 issue 8 2021 34440548 the impact of parkinson's disease (pd) is a common and progressive neurodegenerative disease, caused by the loss of dopaminergic neurons in the substantia nigra pars compacta in the midbrain, which is clinically characterized by a constellation of motor and non-motor manifestations. 2021-08-31 2022-01-13 Not clear
Victor A D Holanda, Julia J Didonet, Manara B B Costa, Adriano H do Nascimento Rangel, Edilson D da Silva, Elaine C Gaviol. Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease. Pharmaceuticals (Basel, Switzerland) vol 14 issue 8 2021 34451872 parkinson disease (pd) is a neurodegenerative disease mainly characterized by the loss of nigral dopaminergic neurons in the substantia nigra pars compacta. 2021-08-31 2022-01-13 Not clear
Eun-Mi Hur, Byoung Dae Le. LRRK2 at the Crossroad of Aging and Parkinson's Disease. Genes vol 12 issue 4 2021 33805527 parkinson's disease (pd) is a heterogeneous neurodegenerative disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the widespread occurrence of proteinaceous inclusions known as lewy bodies and lewy neurites. 2021-08-16 2022-01-13 Not clear
Alexandre Vall\\xc3\\xa9e, Jean-No\\xc3\\xabl Vall\\xc3\\xa9e, Yves Lecarpentie. Potential role of cannabidiol in Parkinson's disease by targeting the WNT/\\xce\\xb2-catenin pathway, oxidative stress and inflammation. Aging vol 13 issue 7 2021 33848261 parkinson's disease (pd) is a major neurodegenerative disease (nd), presenting a progressive degeneration of the nervous system characterized by a loss of dopamine in the substantia nigra pars compacta. 2021-08-16 2022-01-13 Not clear
Falaq Naz, Rahul, Mahino Fatima, Swaleha Naseem, Wasi Khan, Amal Chandra Mondal, Yasir Hasan Siddiqu. Ropinirole silver nanocomposite attenuates neurodegeneration in the transgenic Drosophila melanogaster model of Parkinson's disease. Neuropharmacology vol 177 issue 2021 32707222 parkinson's disease (pd) is a progressive neurodegenerative disease due to the degeneration of dopaminergic neurons in substantia nigra pars compacta of the mid brain. 2021-08-12 2022-01-13 Not clear
Yeojin Bang, Juhee Lim, Hyun Jin Cho. Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease: clues to early diagnosis and effective treatment. Archives of pharmacal research vol 44 issue 6 2021 34145553 parkinson's disease (pd) is a progressive neurodegenerative disease characterized by movement dysfunction due to selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. 2021-08-04 2022-01-13 Not clear
Page: 
1   2   3   4   5   6